NCT01581463View on ClinicalTrials.gov

A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 31, 2012

Conditions
Healthy
Interventions
DRUG

Liothyronine, Sodium

Single 100-microgram (2 X 50 microgram) dose.

Trial Locations (1)

20007

Georgetown University Hospital, Washington D.C.

All Listed Sponsors
lead

Ipe, LLC

INDUSTRY

NCT01581463 - A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects | Biotech Hunter | Biotech Hunter